Ultrasound Imaging Technology for Kidney Stones
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new method of using ultrasound technology to better detect and measure kidney stones. Researchers aim to determine if the Verasonics Data Acquisition System (VDAS) can enhance the visualization and sizing of kidney stones in ultrasound images. Individuals with kidney stones visible on x-rays and who have recently undergone a CT scan may qualify for this trial. As an unphased trial, it offers a unique opportunity to contribute to innovative research that could improve kidney stone diagnosis.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this ultrasound imaging technology is safe for detecting kidney stones?
Research shows that the Verasonics Data Acquisition System (VDAS) is commonly used in medical imaging research. Although not primarily for diagnosing illnesses, it serves as a reliable tool for research at many institutions. The VDAS meets FDA safety standards, ensuring its safe use in studies.
No specific reports of negative effects linked to the VDAS have been found. It is important to note that the VDAS is designed for research, having undergone safety testing in controlled settings. While direct safety data from patient studies is lacking, its widespread use in research worldwide suggests it is safe.
For those considering participation in a trial using the VDAS, this information should provide reassurance about its safety in human studies.12345Why are researchers excited about this trial?
Researchers are excited about the Verasonics Data Acquisition System (VDAS) because it offers a new approach to imaging kidney stones using advanced ultrasound technology. Unlike traditional imaging methods like CT scans or standard ultrasounds, the VDAS uses modified image processing to potentially provide more precise information about the size and location of kidney stones while staying within FDA safety limits. This could lead to more accurate diagnoses and better treatment planning, reducing the need for invasive procedures or excessive radiation exposure.
What evidence suggests that this ultrasound imaging technology is effective for detecting kidney stones?
Research shows that the Verasonics Data Acquisition System (VDAS), used to image participants in this trial, can accurately measure kidney stones with advanced ultrasound methods. Studies have found that this system employs superior image processing to detect and measure kidney stones more precisely. As a result, doctors can see the stone's size and location more clearly. Early results suggest it might also help move stones to less troublesome areas in the kidney. The technology is designed to be safe and aims to improve the accuracy of ultrasound imaging for kidney stones.678910
Who Is on the Research Team?
Michael Bailey
Principal Investigator
University of Washington
Are You a Good Fit for This Trial?
This trial is for adults over 21 who have kidney stones visible on x-ray and can consent to participate. They must also have a recent CT scan. It's not for those under 21, unable to consent, with stones invisible on x-ray, or with certain systemic diseases or renal disorders.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging Procedure
Participants undergo ultrasound imaging to determine the size and location of kidney stones using the Verasonics Data Acquisition System (VDAS)
Data Analysis
Comparison of research ultrasound data with clinical data to assess accuracy
Follow-up
Participants are monitored for any additional data collection from existing medical records
What Are the Treatments Tested in This Trial?
Interventions
- Verasonics Data Acquisition System (VDAS)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Washington
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator